Skip to main content

Table 2 Clinical characteristics among cases and controls.

From: Factors associated with paradoxical immune response to antiretroviral therapy in HIV infected patients: a case control study

Clinical characteristics

Cases (n = 39a)

n (%)

Controls

(n = 160a)

n (%)

Bivariate analyses

   

p-valuee

OR

CI 95%

HIV transmission by intravenous drug use

  

1.00

0.88

0.28-2.7

Yes

4 (10.2)

18 (11.5)

   

No

35 (89.8)

139 (86.6)

   

AIDS defining illness before HAART

  

0.04b

2.34

1.0-5.3

Yes

11 (28.2)

23 (14.4)

   

No

28 (71.8)

137 (85.6)

   

AIDS defined by Rio de Janeiro/Caracas criteria

  

0.53

1.38

0.49-3.85

Yes

5 (12.8)

27 (16.8)

   

No

34 (87.2)

133 (83.1)

   

AIDS defined by CDC adapted criteria

  

0.40

1.52

0.56-4.17

Yes

33 (84.6)

143 (89.3)

   

No

6 (15.4)

17 (10.6)

   

Comorbidities in the previous year

  

0.43

0.75

0.36-1.54

Yes

24 (61.5)

109 (68.1)

   

No

15 (38.4)

51 (31.9)

   

Irregular use of HAART in the previous year

  

0.07c

2.22

0.9-5.3

Yes

9 (23.1)

19 (11.9)

   

No

30 (76.4)

141 (88.1)

   

Concomitant medication in the previous year for more than 30 consecutive days

  

0.00b

0.29

0.1-0.6

Yes

30 (76.9)

79 (49.3)

   

No

9 (23.1)

81 (50.7)

   

Year of HIV diagnosis

  

0.32

1.99

0.64-6.11

Before 1996

5 (12.8)

11 (6.9)

   

After 1996

34 (87.2)

149 (93.1)

   

Year of AIDS diagnosis

  

0.09c

8.59

0.75-97.3

Before 1996

2 (5.1)

1 (0.6)

   

After 1996

37 (94.8)

159 (99.4)

   

Time from HIV diagnosis until first HAART (months)d

39.6 ± 52.2

12.8 ± 26.9

0.57

  
 

Median: 19.5 (IQR: 1.7-63)

Median: 5.5 (IQR: 2.2-10.7)

   

Total time in use of HAART (months)d

36.1 ± 39,7

62.0 ± 32,5

0.00b

  
 

Median: 17 (IQR: 13.7-53.5)

Median: 60 (IQR: 33.2-96)

   

Time in use of last HAART regimen (months)d

19.2 ± 18.3

44.2 ± 28.6

0.00b

  
 

Median: 15 (IQR: 12.2-15.2)

Median: 37 (IQR: 19.2-70.2)

   
  1. n, number; OR, odds ratio; CI 95%, confidence interval of 95%; HAART, highly active antiretroviral therapy; CDC, Centers for Disease Control and Prevention.
  2. a different totals are due to missing data.
  3. b p-value < 0,050.
  4. c p-value < 0,1; variables that could be included in multivariate analysis.
  5. d Continuous data are represented by mean ± standard deviation and by median with interquartile range (IQR).
  6. e Chi-square test or Fisher's exact test were used for comparison of categorical variables between the two groups, as more appropriate. For continuous variables, "Student's" T test was used for comparison of normal distributions between the two groups. For non-normal distributions, it was used the Mann-Whitney test.